Embryonic stem cell trials for macular degeneration: a preliminary report

详细信息    查看全文

• 作者：Prof Steven D Schwartz ; MD^a ; ^{schwartz@jsei.ucla.edu} ; Jean-Pierre Hubschman ; MD^a ; Gad Heilwell ; MD^a ; Valentina Franco-Cardenas ; MD^a ; Carolyn K Pan ; MD^a ; Rosaleen M Ostrick ; MPH^a ; Edmund Mickunas ; MS^b ; Roger Gay ; PhD^b ; Irina Klimanskaya ; PhD^b ; Dr Robert Lanza ; MD^b ; ^{rlanza@advancedcell.com}
• 刊名：The Lancet
• 出版年：2012
• 出版时间：25 February-2 March, 2012
• 年：2012
• 卷：379
• 期：9817
• 页码：713-720
• 全文大小：2810 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Background

It has been 13 years since the discovery of human embryonic stem cells (hESCs). Our report provides the first description of hESC-derived cells transplanted into human patients.

Methods

We started two prospective clinical studies to establish the safety and tolerability of subretinal transplantation of hESC-derived retinal pigment epithelium (RPE) in patients with Stargardt's macular dystrophy and dry age-related macular degeneration¡ªthe leading cause of blindness in the developed world. Preoperative and postoperative ophthalmic examinations included visual acuity, fluorescein angiography, optical coherence tomography, and visual field testing. These studies are registered with , numbers and .

Findings

Controlled hESC differentiation resulted in greater than 99 % pure RPE. The cells displayed typical RPE behaviour and integrated into the host RPE layer forming mature quiescent monolayers after transplantation in animals. The stage of differentiation substantially affected attachment and survival of the cells in vitro after clinical formulation. Lightly pigmented cells attached and spread in a substantially greater proportion (>90 % ) than more darkly pigmented cells after culture. After surgery, structural evidence confirmed cells had attached and continued to persist during our study. We did not identify signs of hyperproliferation, abnormal growth, or immune mediated transplant rejection in either patient during the first 4 months. Although there is little agreement between investigators on visual endpoints in patients with low vision, it is encouraging that during the observation period neither patient lost vision. Best corrected visual acuity improved from hand motions to 20/800 (and improved from 0 to 5 letters on the Early Treatment Diabetic Retinopathy Study [ETDRS] visual acuity chart) in the study eye of the patient with Stargardt's macular dystrophy, and vision also seemed to improve in the patient with dry age-related macular degeneration (from 21 ETDRS letters to 28).

Interpretation

The hESC-derived RPE cells showed no signs of hyperproliferation, tumorigenicity, ectopic tissue formation, or apparent rejection after 4 months. The future therapeutic goal will be to treat patients earlier in the disease processes, potentially increasing the likelihood of photoreceptor and central visual rescue.

Funding

Advanced Cell Technology.